Understanding diagnosis, prognosis, and causes of panvascular disease

A Prospective Research on Diagnosis, Prognosis, and Mechanisms of Panvascular Disease

This project will collect medical records, DNA samples, and follow-up from adults with panvascular disease to see if linking clinical and genetic data can reveal causes and suggest better treatments.

Quick facts

• Study type: Observational
• Enrollment: 1000 (estimated)
• Ages: 18 Years to 80 Years
• Sex: All
• Sponsor: Harbin Medical University (other)
• Locations: 1 site (Harbin, Heilongjiang)
• Trial ID: NCT07151183 on ClinicalTrials.gov

What this trial studies

Researchers will create a standardized cohort of adults with panvascular disease by collecting detailed clinical records, biological samples (including DNA), and long-term follow-up data at Harbin Medical University. No interventions will be given; the study is observational and focuses on comprehensive data and sample collection. Investigators will apply statistical and multi-omics analyses to identify risk factors, molecular pathways, and prognostic markers across multiple vascular beds. The resulting database is intended as a resource for future mechanistic studies and to inform more precise prevention and treatment strategies.

Who should consider this trial

Good fit: Adults aged 18 to 80 with diagnosed or suspected panvascular disease (atherosclerotic lesions in two or more vascular regions) who can give informed consent are the intended participants.

Not a fit: Patients with severe hemodynamic instability, very low ejection fraction (<30%), severe arrhythmias or valvular disease, non-atherosclerotic coronary disorders, severe non-cardiovascular illness, pregnant or breastfeeding individuals, or those who decline consent are not likely to benefit from or be eligible for this protocol.

Why it matters

Potential benefit: If successful, this resource could help identify molecular drivers and risk patterns that enable earlier detection and more personalized treatments for panvascular disease.

How similar studies have performed: Cohort and multi-omics research in cardiovascular disease have previously identified useful associations and biomarkers, but a standardized panvascular-focused cohort of this type is relatively novel.

Eligibility criteria

Inclusion Criteria:

1. Male or female aged 18 to 80 years old;
2. Diagnosed or suspected panvascular disease, defined as the presence of atherosclerotic lesions in at least two or more vascular regions, such as intracranial arteries, carotid arteries, coronary arteries, aorta, and peripheral arteries;
3. Voluntary participation in this study and provision of signed informed consent.

Exclusion Criteria:

1. Severe hemodynamic instability;
2. Severe cardiac dysfunction (EF \< 30%);
3. Severe arrhythmias;
4. Severe valvular heart disease;
5. Cardiomyopathy caused by non-coronary artery diseases;
6. Non-atherosclerotic coronary artery disease (e.g., coronary artery dissection, embolism, etc.);
7. Severe non-cardiovascular diseases;
8. Women who are pregnant or breastfeeding;
9. Individuals who refuse to provide signed informed consent.

Where this trial is running

Harbin, Heilongjiang

• Harbin Medical University — Harbin, Heilongjiang, China (RECRUITING)

Study contacts

• Study coordinator: Tian J Jinwei Tian, MD, PhD

Conditions: Panvascular Diseases, Cardiovascular Diseases, Panvascular disease